Ms. lat. qu. 65 - Le Roman de la Rose

Vorbesitzer: du Roullet

Ms. hebr. oct. 65 - Dine Isur ṿe-heter

Vorbesitzer: Eljāqīm Carmoly; Abraham Merzbacher

Ms. Barth. 65 - Brevier (Winterteil) für St. Bartholomaeus

Vorbesitzer: Bartholomaeusstift Frankfurt am Main

Treatment with the HIV protease inhibitor Nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08).

Downregulation of the unfolded protein response mediates proteasome inhibitor resistance in Multiple Myeloma.The Human Immunodeficieny Virus protease inhibitor nelfinavir activates the unfolded protein response in vitro. We determined dose limiting toxicity and recommended dose for phase II of nelfinavir in combination with the proteasome inhibitor bortezomib. 12 patients with advanced hematological malignancies were treated with nelfinavir (2500 - 5000 mg/d p.o., d 1-14, 3+3 dose escalation) and bortezomib (1.3 mg/m2, d 1, 4, 8, 11; 21 day cycles). A run in phase with nelfinavir monotherapy allowed pharmakokinetic/pharmakodynamic assessment of nelfinavir in the presence or absence of concomittant bortezomib. Endpoints included dose limiting toxicity, activation of the unfolded protein response, proteasome activity, toxicity and response to trial treatment. Nelfinavir 2 x 2500 mg was the recommended phase II dose identified. Nelfinavir alone significantly upregulated expression of proteins related to the unfolded protein response in peripheral blood mononuclear cells and inhibited proteasome activity. Of 10 evaluable patients in the dose escalation cohort, 3 achieved a partial response, 4 stable disease for ≥ 2 cycles, while 3 had progressive disease as best response. In an exploratory extension cohort with 6 relapsed, bortezomib-refractory, lenalidomide-resistant myeloma patients treated at the recommended phase II dose, 3 reached a partial response, 2 a minor response and one progressive disease. The combination of nelfinavir with bortezomib is safe and shows promising signals for activity in advanced, bortezomib-refractory MM. Induction of the unfolded protein response by nelfinavir may overcome the biological features of proteasome inhibitor resistance. (Trial registration NCT01164709).

Zu Epsteins "Randglossen" [Nachricht] : (Monatsschrift 65, 88 ff.)

Samuel Klein

Zu I. Groß' Artikel "Rochade und Notation bei Ibn Esra" [Nachricht] : M.G.W.J., Bd. 65, S. 365-69

Alexander Marx

Ein Gruß für Karl Wolfskehl zum 65. Geburtstage

Bertha Badt

Diagramm [Illustration] : zum Artikel "Anthopologische Untersuchungen über die russisch-polnischen Juden ..." von Dr. Elkind, S. 65 u. ff.

Scan von Monochrom-Mikroform

Ms. Praed. 65 - Moralphilosophisch-aszetische Sammelhandschrift

Vorbesitzer: Dominikanerkloster Frankfurt am Main;

Na 50 Nachlass Arthur Schopenhauer - 'Schopenhauer-Archiv', 65 - Einladung eines in Paris wohnenden Verehrers der Philosophie Schopenhauers mit dem Namen Goll

veröffentlicht in: Schopenhauer, Arthur : Arthur Schopenhauers sämtliche Werke - München : Piper - Bd. 15 : Der Briefwechsel Arthur Schopenhauers ; 2 (1849 - 1860), Nr. 425

Ms. lat. oct. 65 - Paradisus animae

Vorbesitzer: Limburg (?)

Inc. hebr. 65 - Sefer ha-ʿiḳarim

Die Neufoliierung erfolgte anhand des vollständigen Exemplares, es fehlen die Blätter 8, 56 - 58 und 107 - 108. Die fehlenden Blätter 56 - 58 wurden handschriftlich ergänzt, diese Ergänzungen sind als Bl. II - XI foliiert und befinden sich zwischen Bl. 55 und 59. Nach Bl. 9 befindet sich ein als Bl. 9a foliiertes leeres Blatt.

Ms.Ff.F.Stoltze 3. 65 - Brief von Marks Figdor an Friedrich Stoltze

Heinrich Stoltze in New York

Systematic review of current trends of cardiovascular disease (CVD) and association between health insurance coverage and CVD mortality among women aged 60--65 in Texas in 2000--2011

Cardiovascular disease (CVD) is highly preventable, yet it is a leading cause of death among women in Texas. The primary goals of this research were to examine past and current trends of CVD, as well as identify whether there is an association between the insurance coverage and mortality from CVD among women aged 60–65 in Texas between 2000 and 2011. ^ The systematic review of the research is based on the guidelines and recommendations set by the Centre for Reviews and Dissemination for conducting reviews in health care. Over 47 citations of peer-reviewed articles from Ovid MEDLINE and PubMed databases and five websites were identified, of which 7 studies met inclusion criteria for the first systematic review to examine the trends of CVD in Texas. Ten citations of peer-reviewed articles from Ovid MEDLINE and PubMed databases and five web sites were reviewed for the second systematic review (to study the association between insurance coverage and cardiovascular health among Texas women 60–64 years of age), of which 3 studies met inclusion criteria and were included in the research. The results of the study highlighted key gaps in the existing literature and important areas for the further research, as well as determined directions for future public health CVD prevention programs in Texas. ^ Based on the conducted research, the major determinants of premature mortality among women attributed to cardiovascular disease are based on individual level characteristics, more specifically sex, age, race/ethnicity, and education. The results indicate that African American and non-Hispanic white women are more likely to have higher CVD mortality rates than Hispanic women due to higher prevalence of cardiac risk factors. The data also shows higher levels of mortality from CVD in the southeastern United States, with Texas ranking as the third state with the highest prevalence of CVD among women. According to the Texas Department of State Health Services, there are approximately 56,000 deaths caused by CVD annually in Texas, which represents about one death every ten minutes. Coronary artery disease and stroke were the causes of 31.2 percent of all female deaths in Texas in 2009, meaning that approximately 68 women die from any form of cardiac disease in Texas each day. ^ The data of the reviewed studies indicate that women' lack of health insurance was significantly associated with a higher prevalence of cardiovascular disease. The uninsured women were more likely to be unaware of their risk factors and more likely to have undiagnosed diabetes—a co-morbidity factor of CVD. One of the studies also reports strong correlation between state rates of uninsured and lower rates of preventive care. Given these strong correlations, those who were chronically uninsured were at a higher risk of mortality than the insured, due to prolonged periods of time without basic access to preventive and medical care. ^ Suggested recommendations to decrease CVD mortality rates in Texas are consistent with the existing literature and include state policy development that addresses elimination of health disparities, consideration of potential benefits of universal health coverage by the legislative policymakers, and maintenance of solid partnerships between public health agencies and hospitals to educate on, diagnose, and treat CVD among the female population in Texas. ^